- Jun 11, 2021
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (IMPEDE)...
74
- Jun 11, 2021
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies GEN3014 Safety Trial in Relapsed or...
148
- Jun 10, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in RRMM
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Blood Cancer J; 2021...
136
- Jun 10, 2021
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma
MAGNETISMM-2 NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma...
241
- Jun 9, 2021
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...
647
- Jun 9, 2021
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma NCT04892446: Phase 2:...
96